Research Papers:
NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2634 views | HTML 2583 views | ?
Abstract
Jin-Ju Lei1,&, Rou-Jun Peng2,&,*, Bo-Hua Kuang1,&, Zhong-Yu Yuan2, Tao Qin2, Wen-Sheng Liu1, Yun-Miao Guo1, Hui-Qiong Han1, Yi-Fan Lian1, Cheng-Cheng Deng1, Hao-Jiong Zhang1, Li-Zhen Chen1, Qi-Sheng Feng1, Miao Xu1, Lin Feng1, Jin-Xin Bei1,*, Yi-Xin Zeng1,3,*
1Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
2Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
3Peking Union Medical College, Beijing, China
&These authors contributed equally to this work
*These authors jointly directed this study
Correspondence to:
Yi-Xin Zeng, e-mail: [email protected]
Jin-Xin Bei, e-mail: [email protected]
Rou-Jun Peng, e-mail: [email protected]
Keywords: NOP14, breast cancer, NRIP1, Wnt/β-catenin pathway
Received: May 15, 2015 Accepted: July 01, 2015 Published: July 13, 2015
ABSTRACT
NOP14, which is functionally conserved among eukaryotes, has been implicated in cancer development. Here, we show that NOP14 is poorly expressed in breast cancer cells and invasive breast cancer tissues. In vivo and in vitro studies indicated that NOP14 suppressed the tumorigenesis and metastasis of breast cancer cells. Further investigations revealed that NOP14 enhanced ERα expression and inhibited the Wnt/β-catenin pathway by up-regulating NRIP1 expression. Survival analysis indicated that low NOP14 expression was significantly associated with poor overall survival (P = 0.0006) and disease-free survival (P = 0.0007), suggesting that NOP14 is a potential prognostic factor in breast cancer. Taken together, our findings reveal that NOP14 may suppress breast cancer progression and provide new insights into the development of targeted therapeutic agents for breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4573